Background: Type 1 diabetes involves a multiple decision making process on a daily basis.Mobile technology has been widely spread not only as a mean of communication, but also as multi-usage tool involving a large variety of applications, making everyday life more convenient. “D-Partner” (Diabetes Innovations Ltd) is a mobile based application that serves as a self-management tool for type 1 diabetes, including a bolus wizard (with food database),a basal insulin titration manager, as well as, a large number of automated notifications, warnings or reward messages, according to the data imported by the patient. In addition,“D-Partner” serves as a telemedicine tool, as information of meals, insulin dosage, measurements of glucose, blood pressure, body weight, and lab values, may be monitored by the physician through an on-line, web-based platform.

Aim: To investigate the efficacy of "D-Partner" mobile application, in glucose management, in patients with type 1 diabetes.

Methods: 24 patients with type 1 diabetes (14 male, 10 female), with diabetes duration of 14,2±8,8 years, mean age of 37.4±11,7 years and HBA1c >7%, on basal bolus insulin therapy, were randomized to receive either standard care, or standard care plus the ‘D-Partner” application usage. HBA1c, somatometric data, blood pressure, heart rate and hypoglycemia frequency data, were obtained at baseline and 3 months after the intervention.

Results: The intervention group presented a significantly improved glucose control as recorded by HBA1c reduction, compared to the control group (p=0.01). Additionally, hypoglycemia incidence was significantly lower in the intervention group (p=0.04). There were no significant changes in somatometric data blood pressure, and heart rate, among the 2 groups.

Concusion: D-partner, is a mobile based self-management application, that may contribute to a better management of type 1 diabetes, potentially improving the life quality of the patient.


J. Doupis: Consultant; Self; Novo Nordisk Inc., Eli Lilly and Company, Sanofi, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc.. V. Papandreopoulou: None. S. Glykofridi: None. V. Andrianesis: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at